CONVERTIBLE FINANCING AGREEMENTConvertible Financing Agreement • November 9th, 2017 • Entera Bio Ltd. • Biological products, (no disgnostic substances)
Contract Type FiledNovember 9th, 2017 Company IndustryThis Convertible Financing Agreement (the “Agreement”) is made and entered into as of the 31 day of December, 2012, by and among Entera Bio Ltd., a company incorporated under the laws of the State of Israel having its principal offices at 3 Avishai St, Jerusalem 93149, Israel (the “Company”); D.N.A. Biomedical Solutions Ltd. (“D.N.A.”) and the investors set out in Exhibit l hereto (the “Investors”, and each individually, an “Investor”).
CONVERTIBLE FINANCING AGREEMENTConvertible Financing Agreement • November 3rd, 2017 • Entera Bio Ltd. • Biological products, (no disgnostic substances)
Contract Type FiledNovember 3rd, 2017 Company IndustryThis convertible Financing Agreement (the “Agreement”) is made and entered into as of the 8 day of November. 2012, by and among Entera Bio Ltd., a company incorporated under the laws of the State of Israel having its principal offices at 3 Avishai St, Jerusalem 93149, Israel (the “Company”); D.N.A. Biomedical Solutions Ltd. (“D.N.A.”) and the investors set out in Exhibit 1 hereto (the “Investors”, and each individually, an “Investor”).